Dexamethasone in the treatment of COVID-19: Implementation and management of supply for treatment in hospitals

Early data from the RECOVERY trial found dexamethasone to have a clear clinical benefit in COVID-19 patients requiring oxygen or ventilation. This communication recommends clinicians consider using dexamethasone 6mg daily for 10 days, and that local policies are implemented.

SPS commentary:

It is highlighted that dexamethasone was not used in pregnant women in the RECOVERY trial, and prednisolone 40 mg administered by mouth could be considered for pregnant and breastfeeding women.


Department of Health and Social Care